City

Beijing (10)

Nanjing (2)

Guangzhou (1)

Hangzhou (1)

Hefei (1)

Shanghai (1)

Tianjin (1)

Zhenzhou (1)

Overall Status

Recruiting (6)

Unknown status (2)

Enrolling by invitation (1)

Terminated (1)

Phase

phase 2 (3)

phase 1 (2)

phase 3 (2)

phase 1/phase 2 (1)

Collaborator

Nanjing Legend Biotech Co. (1)

Nanjing Legend Biotechnology Co.,Ltd.; The First Affiliated Hospital of USTC west district; Beijing Boren Hospital (1)

Peking University Cancer Hospital & Institute (1)

Intervention

lucar-20s car-t cells (2)

cd19-targeted chimeric antigen receptor (car) t cells (1)

cd19/cd22-bispecific car-t cells (1)

ct-1530 (1)

low-dose decitabine plus anti-pd-1 (1)

methotrexate (1)

rituximab plus chop (1)

sct400 plus chop (1)

Study Documents

Intervention Type

drug (7)

biological (1)

Funder Type

Other (7)

Industry (3)

Study Type

Interventional (8)

Observational (1)

Observational [Patient Registry] (1)

diffuse large b cell lymphoma

Showing NaN - NaN of 10

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED